Mahmood Ladha
Präsident bei DOVA PHARMACEUTICALS, INC.
Vermögen: 503 541 $ am 31.05.2024
Profil
Mahmood Ladha is currently the Head-Strategic Transformation Operations at Swedish Orphan Biovitrum AB and the President at Dova Pharmaceuticals, Inc. Previously, he worked as the Vice President & Head-Transactions at AstraZeneca AB.
He holds undergraduate and MBA degrees from the University of South Carolina.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 10.06.2024 | 18 753 ( 0,01% ) | 503 541 $ | 31.05.2024 |
Aktive Positionen von Mahmood Ladha
| Unternehmen | Position | Beginn |
|---|---|---|
| SWEDISH ORPHAN BIOVITRUM AB | Corporate Officer/Principal | 01.01.2019 |
| DOVA PHARMACEUTICALS, INC. | Präsident | 12.11.2019 |
Ehemalige bekannte Positionen von Mahmood Ladha
| Unternehmen | Position | Ende |
|---|---|---|
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Direktor/Vorstandsmitglied | - |
Ausbildung von Mahmood Ladha
| University of South Carolina | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
| Private Unternehmen | 2 |
|---|---|
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Commercial Services |
Dova Pharmaceuticals, Inc.
 Dova Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dova Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company, which engages in the acquisition, development and commercialization of drug candidates for rare diseases. It focuses on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. Its drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist. The company was founded on March 24, 2016 and is headquartered in Durham, NC. | Health Technology |